Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies-Reference-Cited by-同舟云学术

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Published:2019-09 Issue:9 Volume:6 Page:e576-e587
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Aboud Michael,Orkin Chloe,Podzamczer Daniel,Bogner Johannes R,Baker David,Khuong-Josses Marie-Aude,Parks David,Angelis Konstantinos,Kahl Lesley P,Blair Elizabeth A,Adkison Kimberly,Underwood Mark,Matthews Jessica E,Wynne Brian,Vandermeulen Kati,Gartland Martin,Smith Kimberly

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference27 articles.

1. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV,2018

2. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis;Achhra;Lancet HIV,2016

3. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens;Raffi;HIV Med,2016

4. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial;Fabbiani;J Antimicrob Chemother,2018

5. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV;HIV RES CLIN PRACT;2024

2. Switching Human Immunodeficiency Virus Therapy;Infectious Disease Clinics of North America;2024-09

3. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved;Bioorganic & Medicinal Chemistry;2024-09

4. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study;Infectious Diseases and Therapy;2024-04

5. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04